Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil
about
KASL clinical practice guidelines: management of chronic hepatitis BCost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in ChinaHBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data.Effective screening of informative single nucleotide polymorphisms using the novel method of restriction fragment mass polymorphism.Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions presentHigh-resolution human papillomavirus genotyping by MALDI-TOF mass spectrometry.Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues.Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48.Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations.Establishment of a new quantitative detection approach to adefovir-resistant HBV and its clinical application.Antiviral therapy and resistance with hepatitis B virus infection.Analytical and clinical performances of a restriction fragment mass polymorphism assay for detection and genotyping of a wide spectrum of human papillomaviruses.Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus.Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis BDetection of hepatitis B virus genotypic resistance mutations by coamplification at lower denaturation temperature-PCR coupled with sanger sequencing.Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial.Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.Antiviral therapies: focus on hepatitis B reverse transcriptaseComparison of the efficacy of tenofovir monotherapy versus tenofovir-based combination therapy in adefovir-experienced chronic hepatitis B patients: a systematic review and meta-analysisTreatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B.Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failuresEfficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosisLamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B.The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade.Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patientsResistance issues in treating chronic hepatitis B.Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop.Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment.Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections.Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B.Monotherapy versus combination therapy for the treatment of chronic hepatitis B.
P2860
Q26752475-BA7749E6-4E9A-467C-BAD6-FDA598EF86D9Q28550643-6940BEB7-A4BE-4714-AADF-B216C91C2435Q30741676-2F530E33-317F-40AF-8A7F-7FFD392E7F76Q30838832-C55BD08E-7F7E-4BF3-905F-B28B184653D8Q33267067-35D583F6-BEBB-4007-B418-C7B5E7E37CBBQ33366978-C7632CA4-C1EA-44F7-9D9A-9BF3CBE3EBB6Q33417353-9B1B2E5E-A871-492B-B918-717BDBB4C32DQ33492413-4B8C4A6F-EF81-48DA-990E-A885CF9A9EDAQ33549555-19C0D1DB-3DF2-4FB5-BEF1-98B700595B47Q33610009-07D73DBA-647E-468E-A1B1-ABEBB3FDF013Q33730282-FBCE3AD2-4999-4CE7-9FA7-26D6A98A0A12Q33787531-76971810-D47B-4B88-83E3-666EAEE8EFD0Q33803013-D6081918-6A58-47FA-AAD5-DF30416F3656Q33905600-07F32B51-619B-442E-BE08-2FDA6F111465Q33918275-3B8B188D-D3CB-43FC-85DD-D75FF9BE1026Q34058707-B15A34B3-FAF8-4E74-873F-D7909B4BBFAFQ34339608-7768EB95-C845-4097-96DE-2F36CE4FDD72Q34339613-CF512B5D-E4E2-4309-AE27-35F6C44B97C1Q34471072-43A7F7C3-FB91-440D-BBC2-BB7202EE987EQ34538293-8C13AC85-810D-4E5E-96C0-239AC486A033Q34809263-28EE737F-1263-40DE-9420-D0A87BF17E76Q34948124-44C6BC11-FA9B-418F-BF14-FDBEB207830FQ36153966-28EAA628-2C41-49C7-B8EA-81CDC7BE0432Q36189795-8CF0D138-E5CC-41B4-810C-324E6D3DD204Q36467514-2C092BB6-E46F-4F9B-A4B2-EE466760B588Q36492635-A51C8DCF-BE2D-48B6-BA21-2E7D0591F366Q36492636-05BEBED5-4B62-420B-8E3E-4C85F53AB7ECQ36492640-654718C0-A2F7-4678-B7B5-CC1601DE10A5Q36932092-70F8FBB1-7F22-4842-8920-29FFEC3984F6Q36954038-DE7BD4A7-898D-46DF-999B-4027FBAD703BQ37097615-648F2EA8-92A1-41B8-91EB-635CDA898D76Q37195548-162FEA69-8B73-4D21-9BF5-44AC6057AD48Q37229851-E169B4FF-8721-4068-B5BB-5839D51557D8Q37229870-AD56C038-0DAC-4C6B-97A1-3B7B149EC24FQ37277073-C5B81E39-BA32-445B-A8E7-3EDAEE42388AQ37278097-41F4E0D5-4531-4B60-B3A9-817286838591Q37316713-F19676E8-647B-435C-80BF-ADC827DE2541Q37465040-7647ACA7-50D6-4BB3-B934-7F2FE772E0BCQ37488838-C2A2C8F4-A7D4-47FE-AE5E-F99C827728F8Q37620354-B1B9A98B-3881-4DA7-B800-CF3AEBF3BDB6
P2860
Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Resistance to adefovir dipivox ...... reated with adefovir dipivoxil
@ast
Resistance to adefovir dipivox ...... reated with adefovir dipivoxil
@en
type
label
Resistance to adefovir dipivox ...... reated with adefovir dipivoxil
@ast
Resistance to adefovir dipivox ...... reated with adefovir dipivoxil
@en
prefLabel
Resistance to adefovir dipivox ...... reated with adefovir dipivoxil
@ast
Resistance to adefovir dipivox ...... reated with adefovir dipivoxil
@en
P2093
P2860
P356
P1433
P1476
Resistance to adefovir dipivox ...... reated with adefovir dipivoxil
@en
P2093
P2860
P304
P356
10.1136/GUT.2005.077099
P407
P577
2006-02-04T00:00:00Z